Controle Plasma
Control Plasma is a standardized plasma product used as a reference or quality control material in clinical laboratories, research, and diagnostic assays. It ensures the accuracy and consistency of test results by serving as a baseline for normal or pathological plasma parameters.
Content:
- Source and Preparation:
- Derived from human or animal donors, pooled and processed under strict conditions to ensure uniformity.
- May be normal (from healthy individuals) or pathological (from individuals with specific conditions) to simulate various clinical scenarios.
- Composition:
- Contains plasma proteins (e.g., albumin, globulins, fibrinogen).
- Standardized levels of coagulation factors, electrolytes, and other biochemical markers.
- Stabilization:
- Treated with anticoagulants like citrate or EDTA to prevent clotting.
- Lyophilized or frozen for extended shelf life and ease of storage.
Applications:
- Clinical Diagnostics:
- Coagulation Assays: Used as a reference in tests like PT (Prothrombin Time), APTT (Activated Partial Thromboplastin Time), and fibrinogen assays.
- Hematology: Ensures calibration of automated analyzers and standardization of complete blood counts (CBCs).
- Biochemistry Tests: Serves as a control for electrolyte, enzyme, and protein level measurements.
- Quality Control:
- Ensures consistency and reliability of laboratory results by verifying equipment performance and reagent integrity.
- Used in both internal quality control (IQC) and external quality assurance (EQA) programs.
- Research and Development:
- Acts as a baseline in pharmacokinetic and pharmacodynamic studies.
- Aids in validating diagnostic kits and devices.
- Immunological Studies:
- Provides a reference for immunoassays targeting plasma-derived biomarkers.
- Used in vaccine development to monitor immune responses.
Control Plasma is an essential tool in clinical and research settings, ensuring the accuracy and reliability of plasma-based assays and studies.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|